Dr. Matthew Gubin received his Ph.D. from the University of Missouri. He then completed his postdoctoral work in Dr. Robert Schreiber's lab at Washington University in St. Louis where his research focused on the use of immunogenomics to uncover the targets of T cells during cancer immunotherapy. He demonstrated that during immunotherapy, T cells detect products of mutated proteins in cancer cells and that tumor-specific vaccines targeting these tumor-restricted mutated protein products could provide therapeutic cancer protection in pre-clinical models.

He then became an Instructor at Washington University and a Parker Institute for Cancer Immunotherapy Bridge Scholar, focusing on the use of high dimensional analyses approaches to better understand effective cancer immunotherapy. His current research focuses on investigating the interplay between T cells recognizing tumor antigens and other cells in the immune microenvironment in primary and metastatic tumors and developing improved tumor-specific therapeutic cancer vaccines. 

Read Less